Vertex continues shopping, spending $20M upfront to access Ribometrix's RNA-drugging platform
Vertex, flush with $4 billion in cash and cash equivalents (as of June 30), has been on the prowl to park its excess capital in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
